It's not a stretch to say that USANA Health Sciences, Inc.'s (NYSE:USNA) price-to-earnings (or "P/E") ratio of 15.2x right now seems quite "middle-of-the-road" compared to the market in the United States, where the median P/E ratio is around 17x. While this might not raise any eyebrows, if the P/E ratio is not justified investors could be missing out on a potential opportunity or ignoring looming disappointment.
USANA Health Sciences has been struggling lately as its earnings have declined faster than most other companies. One possibility is that the P/E is moderate because investors think the company's earnings trend will eventually fall in line with most others in the market. If you still like the company, you'd want its earnings trajectory to turn around before making any decisions. Or at the very least, you'd be hoping it doesn't keep underperforming if your plan is to pick up some stock while it's not in favour.
Check out our latest analysis for USANA Health Sciences
NYSE:USNA Price to Earnings Ratio vs Industry January 22nd 2024 Keen to find out how analysts think USANA Health Sciences' future stacks up against the industry? In that case, our free report is a great place to start.
How Is USANA Health Sciences' Growth Trending?
USANA Health Sciences' P/E ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the market.
Taking a look back first, the company's earnings per share growth last year wasn't something to get excited about as it posted a disappointing decline of 22%. As a result, earnings from three years ago have also fallen 42% overall. Accordingly, shareholders would have felt downbeat about the medium-term rates of earnings growth.
Turning to the outlook, the next year should bring diminished returns, with earnings decreasing 6.0% as estimated by the two analysts watching the company. With the market predicted to deliver 10% growth , that's a disappointing outcome.
With this information, we find it concerning that USANA Health Sciences is trading at a fairly similar P/E to the market. It seems most investors are hoping for a turnaround in the company's business prospects, but the analyst cohort is not so confident this will happen. Only the boldest would assume these prices are sustainable as these declining earnings are likely to weigh on the share price eventually.
What We Can Learn From USANA Health Sciences' P/E?
While the price-to-earnings ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of earnings expectations.
Our examination of USANA Health Sciences' analyst forecasts revealed that its outlook for shrinking earnings isn't impacting its P/E as much as we would have predicted. When we see a poor outlook with earnings heading backwards, we suspect share price is at risk of declining, sending the moderate P/E lower. Unless these conditions improve, it's challenging to accept these prices as being reasonable.
Many other vital risk factors can be found on the company's balance sheet. Our free balance sheet analysis for USANA Health Sciences with six simple checks will allow you to discover any risks that could be an issue.
If P/E ratios interest you, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
可以毫不誇張地說 USANA Health Sciences, Inc.與市盈率中位數約爲17倍的美國市場相比,s(紐約證券交易所代碼:USNA)市盈率(或 “市盈率”)目前爲15.2倍似乎相當 “中間路段”。儘管這可能不會引起任何關注,但如果市盈率不合理,投資者可能會錯過潛在的機會或無視迫在眉睫的失望。
USANA Health Sciences最近一直處於困境,因爲其收益下降速度快於大多數其他公司。一種可能性是市盈率適中,因爲投資者認爲該公司的收益趨勢最終將與市場上大多數其他公司的收益趨勢一致。如果你仍然喜歡這家公司,那麼在做出任何決定之前,你會希望其盈利軌跡得到扭轉。或者至少,如果你的計劃是在股市不利的情況下買入一些股票,你希望它不會一直表現不佳。
查看我們對USANA Health Sciences的最新分析
紐約證券交易所:USNA對行業的市盈率 2024年1月22日 想了解分析師如何看待USANA Health Sciences的未來與該行業的對立嗎?在這種情況下,我們的免費報告是一個很好的起點。
USANA 健康科學的增長趨勢如何?
USANA Health Sciences的市盈率對於一家預計只會實現適度增長,重要的是表現與市場保持一致的公司來說是典型的。